VEA
BTAI icon

Virtus ETF Advisers’s BioXcel Therapeutics BTAI Stock Holding History

Virtus ETF Advisers’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-290
Closed -$11.8K – 436
2023
Q3 		$11.8K Sell
290
-29
-9% -$2.93K 0.01% 433
2023
Q2 		$34K Sell
319
-12
-4% -$4K 0.02% 434
2023
Q1 		$98.9K Sell
331
-127
-28% -$54.2K 0.05% 342
2022
Q4 		$158K Sell
458
-252
-35% -$60.9K 0.08% 331
2022
Q3 		$134K Buy
710
+5
+0.7% +$1.16K 0.05% 370
2022
Q2 		$149K Buy
705
+223
+46% +$46.9K 0.06% 319
2022
Q1 		$161K Sell
482
-28
-5% -$8.12K 0.07% 216
2021
Q4 		$166K Buy
510
+163
+47% +$69.9K 0.06% 304
2021
Q3 		$168K Sell
347
-17
-5% -$7.47K 0.07% 315
2021
Q2 		$169K Sell
364
-41
-10% -$22.3K 0.07% 388
2021
Q1 		$280K Buy
405
+7
+2% +$5.63K 0.12% 255
2020
Q4 		$294K Sell
398
-7
-2% -$5.45K 0.12% 223
2020
Q3 		$281K Sell
405
-56
-12% -$42K 0.15% 237
2020
Q2 		$391K Buy
+461
New +$301K 0.19% 204

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus ETF Advisers's BTAI Position: Q4 2023 in Review

Virtus ETF Advisers sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 290 shares — an estimated $11.8K sold.

Virtus ETF Advisers first reported a position in BTAI in Q2 2020 and held it in 14 quarters. The position peaked at $391K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Virtus ETF Advisers reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 290 BioXcel Therapeutics shares in Q4 2023, an estimated $11.8K.
  • Virtus ETF Advisers first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 14 quarters.
  • Virtus ETF Advisers's BioXcel Therapeutics position peaked at $391K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.